1. Home
  2. TBPH vs EVN Comparison

TBPH vs EVN Comparison

Compare TBPH & EVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • EVN
  • Stock Information
  • Founded
  • TBPH 2013
  • EVN 1998
  • Country
  • TBPH United States
  • EVN United States
  • Employees
  • TBPH N/A
  • EVN N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • EVN Investment Bankers/Brokers/Service
  • Sector
  • TBPH Health Care
  • EVN Finance
  • Exchange
  • TBPH Nasdaq
  • EVN Nasdaq
  • Market Cap
  • TBPH 464.5M
  • EVN 410.0M
  • IPO Year
  • TBPH N/A
  • EVN N/A
  • Fundamental
  • Price
  • TBPH $9.30
  • EVN $9.83
  • Analyst Decision
  • TBPH Buy
  • EVN
  • Analyst Count
  • TBPH 3
  • EVN 0
  • Target Price
  • TBPH $11.33
  • EVN N/A
  • AVG Volume (30 Days)
  • TBPH 224.8K
  • EVN 101.2K
  • Earning Date
  • TBPH 05-12-2025
  • EVN 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • EVN 4.78%
  • EPS Growth
  • TBPH N/A
  • EVN N/A
  • EPS
  • TBPH N/A
  • EVN 0.34
  • Revenue
  • TBPH $64,381,000.00
  • EVN N/A
  • Revenue This Year
  • TBPH $51.09
  • EVN N/A
  • Revenue Next Year
  • TBPH N/A
  • EVN N/A
  • P/E Ratio
  • TBPH N/A
  • EVN $29.94
  • Revenue Growth
  • TBPH 12.12
  • EVN N/A
  • 52 Week Low
  • TBPH $7.44
  • EVN $8.64
  • 52 Week High
  • TBPH $10.90
  • EVN $10.45
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 58.45
  • EVN 36.57
  • Support Level
  • TBPH $8.44
  • EVN $9.71
  • Resistance Level
  • TBPH $8.82
  • EVN $10.12
  • Average True Range (ATR)
  • TBPH 0.45
  • EVN 0.23
  • MACD
  • TBPH 0.08
  • EVN -0.01
  • Stochastic Oscillator
  • TBPH 94.70
  • EVN 31.46

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About EVN Eaton Vance Municipal Income Trust

Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.

Share on Social Networks: